What type of study is this?

September 18, 2025npj Precision OncologyOpen Access

Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC

View Full Paper

Ask AI

Bookmark

The PD-L1 QCS-PMSTC method improved classification of patients, leading to a higher prevalence of biomarker positivity.
Using PD-L1 QCS-PMSTC showed a hazard ratio of 0.62 in treatment outcomes, compared to 0.69 for visual scoring.
Analysis included 768 WSI from the MYSTIC trial, with significant improvements in biomarker identification over traditional scoring.
This approach supports the adoption of quantitative methods in clinical settings to enhance decision-making for immunotherapy.

No takes yet. Share an insight, caveat, or question.

Computer vision method improves patient classification by PD-L1 levels in metastatic lung cancer, indicating better treatment outcomes.

Lesniak et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark